Nurix Therapeutics Presents Preclinical Data on NX|5948 and GS ...

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024.

Nurix Therapeutics Presents Preclinical Data from Two

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024.

Nurix Therapeutics Presents Preclinical Data On NX-5948 And GS ...

Nurix Therapeutics presented preclinical data on NX-5948 and GS-6791 at ACR Convergence 2024, highlighting their potential in treating ...

Nurix Therapeutics

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024. November 5 ...

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial ...

... preclinical data demonstrating cell-type selective degradation of targeted proteins by DACs. ... GS-6791 (previously NX-0479): GS-6791 is a potent ...

Press Releases - Nurix Therapeutics, Inc.

Corporate Profile · November 17, 2024, Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, ...

Nurix Therapeutics, Inc.: Investor Relations

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024. November 5 ...

Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial ...

Nurix also plans to complete preclinical studies to enable an investigational new drug (IND) application for NX-5948 in autoimmune indications. Additional ...

Nurix Therapeutics Presents Preclinical Data - Moomoo News

NurixTherapeutics Presents Preclinical Data From Two Autoimmune and Inflammatory Disease Programs, Nx-5948 and Gs-6791, at Acr Convergence ...

Investors - Nurix Therapeutics, Inc.

... G. O'Connor, M.D., chief medical officer of Nurix. “These data support our decision to advance NX-5948 into the ongoing Phase 1b expansion ...

Nurix Therapeutics, Inc. - Press Release Distribution and Management

Search Filters · Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024.

Health Stocks News on X: "Nurix Therapeutics Presents Preclinical ...

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence ...

ACRES Commercial Realty-Nurix Therapeutics Presents Preclinical ...

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024. ACR ACRES ...

Market Wire News - X.com

News; $NRIX Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, ...

Initial Findings From a First-in-Human Phase 1a/b Trial of NX-5948 ...

preclinical efficacy in a mouse brain lymphoma disease model. ... physicians for participating in the NX-5948-301 study, which was sponsored by Nurix.

Nurix Therapeutics Will Present Preclinical Data From NX-5948 ...

... And GS-6791/NX-0479 In Collaboration With Gilead Sciences And Also In IND-enabling... Benzinga · Oct 9 04:24. 1min. Nurix Therapeutics (NRIX.US).

Nurix Therapeutics - BioSpace

Nurix Therapeutics · Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence ...

stock scope on X: "$NRIX - Nurix Therapeutics Presents Preclinical ...

NRIX - Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, ...

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune ...

NRIX | Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR ...

Nurix Therapeutics Will Present Preclinical Data From NX-5948 ...

... , Currently In Phase 1b For B-Cell Malignancies And In IND-Enabling Studies For Autoimmune Disease, And GS-6791/NX-0479 In Collaboration.